ACLX / CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year. more_horizontal

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles h more_horizontal

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogr more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of thi more_horizontal

Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by th more_horizontal

Analysts at Baird say they still like the long-term outlook for biotechnology company Arcellx Inc (NASDAQ:ACLX) after a clinical trial for its invest more_horizontal

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of $2.52. This compares to loss of $1.56 pe more_horizontal

Arcellx, Inc. (ACLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong more_horizontal